Targets › PTGIR
7 programs from 7 companies in 24 trials: 11 Phase 3, 6 Phase 2, 5 Phase 4, 2 Phase 1; Cardiovascular, Respiratory, Gastroenterology; next expected readout Dec 2026.
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase. (UniProt, P43119)
Open in Phaseline: the race on PTGIR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Liquidia Technologies | Treprostinil (LIQ861) Prostanoid IP receptor agonist | PTGIR | Phase 4 | Pulmonary Arterial Hypertension (PAH); Primary Pulmonary Hypertension; Pulmonary Hypertension Due to Lung Disease (Disorder); Pulmonary Arterial Hypertension | May 2027 |
| United Therapeutics | Treprostinil Prostanoid IP receptor agonist | PTGIR | Phase 4 | Pulmonary Arterial Hypertension; Progressive Pulmonary Fibrosis | Nov 2027 |
| University of Sao Paulo General Hospital | Iloprost Prostanoid IP receptor agonist | PTGIR | Phase 4 | Pulmonary Arterial Hypertension (PAH) | Jul 2028 |
| Insmed | Treprostinil Prostanoid IP receptor agonist | PTGIR | Phase 3 | Pulmonary Arterial Hypertension; Pulmonary Hypertension; Progressive Pulmonary Fibrosis; Hepatic Impairment … | Dec 2026 |
| Johnson & Johnson (Janssen) | selexipag Prostanoid IP receptor agonist | PTGIR | Phase 3 | Hypertension, Pulmonary; Pulmonary Arterial Hypertension | Dec 2026 |
| Pär Johansson | Iloprost Prostanoid IP receptor agonist | PTGIR | Phase 2 | Acute Respiratory Failure | Sep 2027 |
| Montreal Heart Institute | Epoprostenol Sodium Prostacyclin receptor (IP receptor) agonist | PTGIR | Phase 2 | Right Heart Failure | May 2028 |
Pulmonary Arterial Hypertension (8) Pulmonary Arterial Hypertension (PAH) (2) Pulmonary Hypertension (2) Progressive Pulmonary Fibrosis (2) COPD (Chronic Obstructive Pulmonary Disease) (2) Hypertension, Pulmonary (2) Hepatic Impairment (1) Ischemia Reperfusion Injury (1) Acute Respiratory Failure (1) Primary Pulmonary Hypertension (1) Pulmonary Hypertension Due to Lung Disease (Disorder) (1) Right Heart Failure (1)
small molecule (7)
University of Sao Paulo General Hospital (1) Insmed (1) Johnson & Johnson (Janssen) (1) Pär Johansson (1) Liquidia Technologies (1) Montreal Heart Institute (1) United Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.